Key facts
- This page summarizes Darren C. Newberry's Form 4 filing for CARMAX INC (KMX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 03 May 2024, 16:33.
Darren C. Newberry - 01 May 2024 Form 4 Insider Report for CARMAX INC (KMX)
- SEC form
- 4
- Accepted by SEC
- 03 May 2024, 16:33:24 UTC
- Prior SEC filing
- 12 Apr 2024
- Next SEC filing
- 07 May 2024
- Source filing
- View source filing
- Reporting owner signature
- Christine Carter, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Darren C. Newberry filed Form 4 for CARMAX INC (KMX) on 03 May 2024.
Change
- Previous filing in this sequence was filed on 12 Apr 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KMX
transaction
Derivative
Stock Options (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +20,452
- Change %
- Price
- $0.000000
- Shares after
- 20,452
- Date
- 01 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,452
- Exercise price
- $67.21
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The stock options were granted in tandem with stock appreciation rights (SARS). Accordingly, the exercise of one results in the surrender to the Company of the other. The SARS become exercisable only following a change in control of the Company as set forth in the Company's 2002 Stock Incentive Plan, as amended and restated. Once exercisable, the SARS would entitle the Reporting Person to receive the cash value of the options in lieu of exercising the options.
Footnote F2
The stock options become exercisable with respect to one-fourth of the underlying shares of Common Stock on each of May 1, 2025, May 1, 2026, May 1, 2027 and May 1, 2028.